Lung Cancer
<ѻý class="page-description">More in Lung Cancer
A look back at some of the newsworthy developments of 2024
Largest survival benefit observed in patients who entered a cessation program within 6 months
Debate highlights pros and cons of the new recommendation
Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone
Study raises questions about how to assess patient risk, experts say
Latest negative results emphasize "critical" aspect of immunotherapy timing
EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy
Actual rates for 2021 lagged behind projections
Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan
However, plinabulin plus docetaxel still "not ready for prime time," expert says
Absolute improvement of almost 30%, doubling of duration of response with savolitinib
Two-trial analysis shows about a 40% decreased risk of disease recurrence or death
Novel agent nearly halved risk of progression as first-line therapy in phase III trial
Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy
